Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 16;19(6):e06603.
doi: 10.2903/j.efsa.2021.6603. eCollection 2021 Jun.

Efficacy of an infant formula manufactured from a specific protein hydrolysate derived from whey protein isolate and concentrate produced by Société des Produits Nestlé S.A. in reducing the risk of developing atopic dermatitis

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA); Jacqueline Castenmiller, Karen-Ildico Hirsch-Ernst, John Kearney, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Dominique Turck, Marco Vinceti, Rosangela Marchelli, Henk van Loveren, Céline Dumas, Ariane Titz, Stefaan de Henauw

Efficacy of an infant formula manufactured from a specific protein hydrolysate derived from whey protein isolate and concentrate produced by Société des Produits Nestlé S.A. in reducing the risk of developing atopic dermatitis

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) et al. EFSA J. .

Abstract

The European Commission asked EFSA to evaluate the efficacy of an infant formula, containing a specific protein hydrolysate derived from whey protein isolate and concentrate and manufactured by Société des Produits Nestlé S.A., in reducing the risk of developing atopic dermatitis in infants with a family history of allergy. This was following the submission of a dossier by Société des Produits Nestlé S.A. to the European Commission, in the context of Regulation (EU) 2016/127. The protein hydrolysate from which the infant formula is produced is included in Annex I and II of Commission delegated Regulation (EU) 2016/127 as suitable protein source for the manufacture of infant and follow-on formulae. This opinion does not cover the assessment of the nutritional safety and suitability of the infant formula or the safety of the food enzymes used in the manufacture of the protein hydrolysate. The Panel considers that, in relation to the effect that is claimed, the infant formula under evaluation is not sufficiently characterised with respect to the molecular weight distribution of peptides. From the human intervention studies submitted, no conclusions could be drawn on the efficacy of the infant formula in reducing the risk of developing atopic dermatitis. The Panel concludes that a cause-and-effect relationship has not been established between the consumption of the infant formula under evaluation and the reduction in the risk of developing atopic dermatitis in infants with a family history of allergy.

Keywords: allergy; atopic dermatitis; characterisation; clinical trial; formula; infants; protein hydrolysate.

PubMed Disclaimer

References

    1. Akimoto K, Saito H, Akasawa A and Iikura Y, 1997. Preventative effect of a whey hydrolyzed formula [Nestle, NAN H.A.] on the development of allergic symptoms in infants. Arerugi (Japanese Journal of Allergology), 46, 1044–1051. - PubMed
    1. Becker A, Watson W, Ferguson A, Dimich‐Ward H and Chan‐Yeung M, 2004. The Canadian asthma primary prevention study: outcomes at 2 years of age. Journal of Allergy and Clinical Immunology, 113, 650–656. 10.1016/j.jaci.2004.01.754 - DOI - PubMed
    1. von Berg A, Koletzko S, Grubl A, Filipiak‐Pittroff B, Wichmann HE, Bauer CP, Reinhardt D, Berdel D; and the German Infant Nutritional Intervention Study Group, 2003. The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life: the German Infant Nutritional Intervention Study, a randomized double‐blind trial. Journal of Allergy and Clinical Immunology, 111, 533–540. 10.1067/mai.2003.101 - DOI - PubMed
    1. von Berg A, Koletzko S, Filipiak‐Pittroff B, Laubereau B, Grübl A, Wichmann H‐E, Bauer C‐P, Reinhardt D and Berdel D, 2007. Certain hydrolyzed formulas reduce the incidence of atopic dermatitis but not that of asthma: three‐year results of the German Infant Nutritional Intervention Study. Journal of Allergy and Clinical Immunology, 119, 718–725. 10.1016/j.jaci.2006.11.017 - DOI - PubMed
    1. von Berg A, Filipiak‐Pittroff B, Kramer U, Link E, Bollrath C, Brockow I, Koletzko S, Grubl A, Heinrich J, Wichmann HE, Bauer CP, Reinhardt D, Berdel D; the GINIplus study group, 2008. Preventive effect of hydrolyzed infant formulas persists until age 6 years: long‐term results from the German Infant Nutritional Intervention Study (GINI). Journal of Allergy and Clinical Immunology, 121, 1442–1447. 10.1016/j.jaci.2008.04.021 - DOI - PubMed

LinkOut - more resources